A ccording to newly released recommendations from the U.S. Preventive Services Task Force (USPSTF), clients and clinicians should consider overall risks for coronary heart disease and gastrointestinal bleeding before deciding whether to use aspirin to prevent myocardial infarction or stroke (USPSTF, 2009 300 meta-analysis of the risks and benefits of aspirin. The Task Force found a difference between genders regarding the benefits and harms of aspirin. The Task Force also found evidence that aspirin decreases the incidence of first myocardial infarctions in men and first strokes in women. The new recommendat ions provide more agespecific and sex-specific guidance about harms and benefits than do the 2002 recommendation s. The recommendations differ for men and women because of the differences in the epidemiology of cardiova scular disease. Men 45 to 79 years old should be encouraged to use aspirin when the potential benefit of a reduction in myocardial infarctions outwe ighs the potential harm of an increase in gastrointestinal hemorrhage. Women 55 to 79 years old should be encouraged to use aspirin when the potential benefit of a reduction in ischemic strokes outweighs the potential harm of an increase in gastrointestinal hemorrhage. For both of these recommendation s, there is high certainty that the net benefit is substantial. For men and women 80 years or older, insufficient evidence exists to assess the balance of benefits and harms of aspirin for preventing cardiova scular disease . Women younger than 55 years and men younger than 45 years should not be encouraged to use aspirin to prevent cardio vascular disease. For this recommendation, moderate or high certainty exists that there is no net benefit or that the harms outweigh the benefits.
Men have a higher risk for coronary heart disease and these events commonly occur at a younger age than among women. After the age of 40, men have a 49% lifetime risk and women have a 32% lifetime risk for a coronary heart disease event. Median age at the first myocardial infarction is 65.8 years for men and 70.4 years for women. Myocardial infarction mortality rates also differ between the sexes. This difference is, in part, possibly attributable to the older age of women at the first event. Women are more likely to die of myocardial infarction. Twenty-five percent of men and 38% of women die within 1 year of the first event.
Although the incidence of stroke is greater among men, more women die of stroke due to their longer life expectancy. According to data examined by the USPSTF, the lO-year risk for initial ischemic stroke at age 55 years is 1.8% for women and 2.4% for men. The risk increases to 3.9% for women and 5.8% for men at age 65. Between ages 55 and 75, the lifetime risk for ischemic stroke is greater among women (approximatel y 17% to 18%) than among men (13% to 14%). The lifetime risk decreases to 14% for women and 8% for men after age 75.
The optimum dose of aspirin to prevent cardiovascular disease events is not known. However, the Task Force statement points to primary prevention trials that have demonstrated benefits with dosages of 75 or 100 mg/day and 100 or 325 mg every other day. The Task Force statement indicates that a dosage of approximately 75 mg/day seems to be as effective as higher dosages that may bring an increased risk of gastrointestinal bleeding: 
